Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 2
1977 1
1979 4
1980 3
1981 1
1985 2
1986 1
1987 1
1988 2
1989 2
1992 2
1993 1
1994 2
1995 2
1996 3
1997 3
1998 9
2000 1
2001 4
2002 2
2003 6
2004 1
2005 1
2006 6
2007 9
2008 2
2009 2
2010 1
2011 4
2012 3
2013 8
2014 4
2015 6
2016 6
2017 4
2018 4
2019 8
2020 3
2021 8
2022 11
2023 9
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: latham cl. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Late-life exercise mitigates skeletal muscle epigenetic aging.
Murach KA, Dimet-Wiley AL, Wen Y, Brightwell CR, Latham CM, Dungan CM, Fry CS, Watowich SJ. Murach KA, et al. Among authors: latham cm. Aging Cell. 2022 Jan;21(1):e13527. doi: 10.1111/acel.13527. Epub 2021 Dec 21. Aging Cell. 2022. PMID: 34932867 Free PMC article.
GDF8 inhibition enhances musculoskeletal recovery and mitigates posttraumatic osteoarthritis following joint injury.
Brightwell CR, Latham CM, Keeble AR, Thomas NT, Owen AM, Reeves KA, Long DE, Patrick M, Gonzalez-Velez S, Abed V, Annamalai RT, Jacobs C, Conley CE, Hawk GS, Stone AV, Fry JL, Thompson KL, Johnson DL, Noehren B, Fry CS. Brightwell CR, et al. Among authors: latham cm. Sci Adv. 2023 Dec;9(48):eadi9134. doi: 10.1126/sciadv.adi9134. Epub 2023 Nov 29. Sci Adv. 2023. PMID: 38019905 Free PMC article.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Español CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D'Amico R, Smith KY, Vandermeulen K, Spreen WR. Overton ET, et al. Among authors: latham cl. Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020. Clin Infect Dis. 2023. PMID: 36660819 Free PMC article. Clinical Trial.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AG. Orkin C, et al. Among authors: latham cl. Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370. Clin Infect Dis. 2023. PMID: 37340869 Free PMC article.
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
Jonsson-Oldenbüttel C, Ghosn J, van der Valk M, Florence E, Vera F, De Wit S, Rami A, Bonnet F, Hocqueloux L, Hove K, Ait-Khaled M, DeMoor R, Bontempo G, Latham CL, Gutner CA, Iyer S, Gill M, Czarnogorski M, D'Amico R, van Wyk J. Jonsson-Oldenbüttel C, et al. Among authors: latham cl. J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):472-480. doi: 10.1097/QAI.0000000000003448. Epub 2024 Jul 9. J Acquir Immune Defic Syndr. 2024. PMID: 38985445 Free PMC article. Clinical Trial.
153 results